Research and Clinical Trials

Title  
F. Hoffmann-La Roche Ltd WO39210: A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Atezolizumab (Anti-PDL1 Antibody) as Adjuvant Therapy in Patients With Renal Cell Carcinoma at High Risk of Developing Metastasis Following
Brief Description  
Disease free survival (DFS) from baseline until first occurrence of DFS event.
Who may be Eligible  
Please contact us for eligibility criteria.
Speciality/Disorder  
Kidney
Status  
OPEN
Start Date  
07/10/2017
IRB Number  
00021440
Principal Investigator  
Burgess, Earle Frederick
Contact Name  
Neil L West

For More Information, Contact  Neil  L, West
Phone:  704-863-6187 Fax:    
Email:  neil.west@carolinashealthcare.org
Address:101 WT Harris Blvd Bldg 1000 Suite 1214 Charlotte, NC 28262
Close